Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
Quarterly buybacks reduced shares outstanding by 6.8%, while operating cash use fell 52% year over year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lite Strategy (Nasdaq: LITS) reported fiscal 2027 first-quarter net income of $16.0 million, primarily associated with remeasurement of its Litecoin treasury. Litecoin appreciated 60% during the quarter ended September 30, 2026. The company repurchased approximately 2.2 million shares at an average $1.08 each, reducing shares outstanding by 6.8%.
General and administrative expenses fell 24% to $2.4 million, while net cash used in operations declined 52% to $2.2 million year over year. Covered calls generated approximately $130,000 in premium proceeds. At September 30, it held 751,798 LTC worth $50.5 million, including 64,700 LTC pledged as options collateral, and $4.3 million in cash and equivalents. Total assets were $58.4 million against $1.7 million in liabilities, with no debt. October repurchases added 825,181 shares at a weighted-average $1.27 each; shares outstanding totaled 29,884,653 on October 30.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point$16.0 million net income primarily reflected Litecoin treasury remeasurement as LTC appreciated 60% during the quarter.
- Moderate pointApproximately 2.2 million shares repurchased at $1.08 on average reduced first-quarter shares outstanding by 6.8%.
- Moderate point825,181 additional shares repurchased in October 2026 at a weighted-average price of $1.27 each.
- Moderate pointOperating cash use fell 52% year over year to $2.2 million in the first quarter.
- Moderate pointGeneral and administrative expenses fell 24% year over year to $2.4 million in the first quarter.
9 minor points
- Minor pointLow 20% range discount to NAV was consistently maintained on first-quarter repurchases.
- Minor pointApproximately 18% of aggregate shares had been repurchased from program commencement through September 30, 2026.
- Minor pointApproximately $130,000 in covered-call premiums brought cumulative proceeds to approximately $1.1 million in just over a year.
- Minor pointNo outstanding debt; share buybacks remained funded entirely through active treasury management operations.
- Minor point. Forward-looking: it has not happened yet and may not happen.Fiscal 2027 plans include selective acquisitions and strategic partnerships to build operating activity around Litecoin.
- Minor point. Forward-looking: it has not happened yet and may not happen.Institutional investor relations expansion is planned for the remainder of fiscal 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Lead institutional investment in LitVM provides participation as the Litecoin smart-contract platform advances toward mainnet launch.
- Minor pointPreliminary voruciclib results showed immune-cell subset modulation in studies outside the body, supporting further animal-model development.
- Minor point. Forward-looking: it has not happened yet and may not happen.Voruciclib and zandelisib monetization remains under assessment through out-licensing or sales as potential non-dilutive capital sources.
Negative
- Moderate point64,700 LTC pledged as collateral for covered-call options encumbered part of the treasury at September 30, 2026.
Key Figures
- Net income
- $16.0 million
- Fiscal 2027 first quarter; primarily associated with remeasurement of the LTC treasury asset
- Litecoin appreciation
- 60%
- During the fiscal first quarter
- Shares repurchased
- Approximately 2.2 million at an average price of $1.08 per share
- Fiscal 2027 first quarter
- General and administrative expenses
- $2.4 million, down 24%
- Versus the prior-year comparative quarter
- Net cash used in operating activities
- $2.2 million, down 52%
- Versus the prior-year comparative quarter
- Litecoin treasury holdings
- 751,798 LTC; fair value of $50.5 million
- At September 30, 2026
- Covered-call premium proceeds
- Approximately $130,000
- Generated during the current period
- Shares repurchased since program commencement
- Approximately 18% of aggregate shares
- Through September 30, 2026
Previous Earnings Reports
-
Annual results established the treasury strategy, share repurchases, covered-call proceeds, and debt-free operations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
net asset value financial
covered call financial
zero-knowledge technical
layer-2 technical
cdk9 inhibitor medical
ex vivo medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Share Repurchases Retire a Further
6.8% of Outstanding Shares Below Net Asset Value - Cash Used in Operations Down
52% and G&A Expenses Down24% Year over Year - Balance Sheet Remains Debt-Free
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (“LTC”) as its primary treasury reserve asset, today announced financial results for its fiscal 2027 first quarter ended September 30, 2026.
The first quarter of fiscal 2027 opened Lite Strategy’s second fiscal year operating under its Litecoin treasury strategy. With Litecoin appreciating
“Our first quarter of fiscal 2027 showed what an actively managed Litecoin treasury can deliver,” said Jay File, CEO & CFO of Lite Strategy. “When we reported fiscal year 2026 results, we said this year would be about accretive buybacks, recurring yield and lower costs. In the first quarter, we repurchased another 2.2 million of our shares at a meaningful discount to net asset value, saw our covered call program continue to generate cash, significantly reduced general and administrative expenses and cut the cash used in our operations by more than half, all with a debt-free balance sheet. Every capital allocation decision we make is measured against whether we expect it to increase the value behind every share of LITS common stock. Looking ahead, our focus is on proving that a digital asset treasury and institutional-grade fiscal discipline can thrive together while selectively evaluating M&A and strategic opportunities that can expand our treasury operations and drive business development across the Litecoin ecosystem.”
Fiscal 2027 First Quarter and Recent Highlights
- Repurchased approximately 2.2 million LITS shares at an average price of
$1.08 per share during the first fiscal quarter of 2027, consistently maintaining the discount to net asset value (NAV) in the low20% range and bringing the percentage of aggregate shares repurchased since program commencement to September 30, 2026, to approximately18% - Premium proceeds of approximately
$130,000 generated from covered call program during the current period, bringing cumulative proceeds of approximately$1.1 million in just over a year from program initiation - Reduced general and administrative expenses
24% to$2.4 million and cut net cash used in operating activities52% to$2.2 million versus the prior year comparative quarter - Held 751,798 LTC with a fair value of
$50.5 million at September 30, 2026, including 64,700 LTC pledged as collateral for covered call options - Maintained a debt-free balance sheet, continuing to fund the share buyback program entirely through active treasury management operations
"Litecoin just marked fifteen years of continuous operation, and in that time the network has never stopped doing what it was built to do: move value quickly, cheaply and securely for anyone, anywhere," said Charlie Lee, Lite Strategy Board Member and creator of Litecoin. "With regulators now recognizing Litecoin as a digital commodity, and LitVM bringing smart contracts to the network, Litecoin is evolving from a pure payment rail into a broader platform. Lite Strategy gives investors a direct way to take part in that growth, and I'm proud to support a company that is actively investing in the Litecoin ecosystem rather than simply holding the asset."
Cash and Liquidity
At September 30, 2026, Lite Strategy held
Business Update and Continued Strategic Focus
Management’s primary objective remains focused on increasing the LTC backing behind every share of LITS common stock. With the active treasury program now established following its first 12-months of execution and while operating on a debt-free basis, the Company’s fiscal 2027 priorities focus on building operating activity around the Litecoin ecosystem, including through selective acquisitions and strategic partnerships, broadening its institutional investor base, and deploying capital only where it is accretive on a per-share basis. All three rest on institutional-grade custody, internal controls and SEC and Nasdaq compliance already established during our first year of operations as a digital asset treasury company.
The regulatory foundation for Litecoin continues to strengthen. The SEC’s March 2026 Digital Asset Interpretation identified LTC as a digital commodity rather than a security, and the CFTC confirmed it will continue to regulate LTC on that basis. In August 2026, the SEC built on that guidance by proposing Regulation Crypto Assets; its public comment period closed on October 20, 2026. Together, these actions give corporate treasuries, asset managers and other institutions a clearer basis for evaluating LTC exposure than they had a year ago. The Company continues to monitor legislative and regulatory developments.
Lite Strategy is also investing directly in the growth of the Litecoin ecosystem. The Company is the lead institutional investor in LitVM, the first zero-knowledge Layer-2 platform bringing smart contract capability to the Litecoin network, as LitVM advances toward its mainnet launch. LitVM is designed to extend Litecoin from a payment network into a programmable one, supporting decentralized finance, stablecoin issuance and tokenized assets, with LTC serving as the network’s native token. Broader use of Litecoin across these applications supports the long-term utility of the LTC held in the Company’s treasury.
For the remainder of fiscal 2027, management intends to expand its institutional investor relations program and continue building the case for LTC as an institutional asset. Management believes Lite Strategy is well positioned as one of the only pure-play, publicly traded vehicles offering investors liquid, regulated exposure to Litecoin’s growth, without the custody, security and operational complexity of holding the asset directly.
Pharmaceutical Assets
Lite Strategy continues pre-clinical evaluation of voruciclib, an oral CDK9 inhibitor, in non-oncology indications. Preliminary ex vivo study results showed modulation of immune cell subsets, supporting further development in animal models. The Company continues to assess out-licensing or sale opportunities for voruciclib and zandelisib as potential sources of non-dilutive capital.
About Lite Strategy
Lite Strategy Inc. (Nasdaq: LITS) is a San Diego-based digital asset treasury company that holds LTC as a primary reserve asset and pursues capital markets strategies designed to generate income from those holdings while retaining long-term exposure. Formerly MEI Pharma Inc., the Company adopted its Litecoin treasury strategy in 2025 to diversify reserves, enhance capital efficiency and align with emerging financial technologies. Lite Strategy also retains a portfolio of pharmaceutical assets that it is managing for out-licensing or sale. More information is available at www.litestrategy.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding LTC and its potential performance, the Company’s Litecoin treasury strategy, the share repurchase program, out-licensing, regulatory foundation, or sale of pharmaceutical assets and the sufficiency of the Company’s capital resources. These statements are subject to risks and uncertainties, including volatility in the price of LTC, the regulatory treatment of digital assets, the Company’s ability to maintain compliance with Nasdaq listing standards, potential dilution from outstanding warrants and options and the other risks described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.
Contacts
Investor Relations:
Alliance Advisors IR
Adele Carey
SVP, Investor Relations
investor@litestrategy.com
Public Relations:
Impact3
Casey Wilson
Director of Public Relations
media@litestrategy.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What drove Lite Strategy's fiscal 2027 first-quarter net income?
Lite Strategy reported $16.0 million in net income, primarily associated with remeasurement of its Litecoin treasury as of September 30, 2026. Litecoin appreciated 60% during the quarter.
How much stock did LITS repurchase in its fiscal 2027 first quarter?
Lite Strategy repurchased approximately 2.2 million shares at an average price of $1.08 per share, reducing shares outstanding by 6.8%. Repurchases consistently maintained a discount to net asset value in the low 20% range.
What is Lite Strategy doing with its pharmaceutical assets?
Lite Strategy continues pre-clinical evaluation of voruciclib in non-oncology indications and is assessing out-licensing or sale opportunities for voruciclib and zandelisib. Preliminary studies outside the body showed modulation of immune-cell subsets, supporting further development in animal models. Potential asset transactions are being assessed as sources of non-dilutive capital.